Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70075 ↗At a glance
Vergleichsstudie in Clinical Transplantation, 2025. Written by Stalin Canizares and 4 co-authors. Institution: Department of Transplant Surgery, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Major MEDLINE topics: Kidney Transplantation, Abatacept, Tacrolimus, Graft Rejection. Cited 1 times so far (Crossref); 29 references.
Abstract (original language)
Calcineurin inhibitors have been the choice for maintenance immunosuppression (IS) in kidney transplant recipients (KTR), but they are associated with nephrotoxicity and metabolic side effects. We aim to compare the long‐term outcomes of KTR on belatacept (bela) versus tacrolimus (tac) IS, in all KTRs and various subgroups. Using the UNOS‐STAR files, we identified adult first‐KTR from 2010 to 2022. Patients were categorized based on maintenance‐IS at index transplant admission by creating a propensity score matched cohort at 1:5 rate using several clinical characteristics. Primary outcomes included patient death, graft failure (GF), and death‐censored graft failure (DCGF). Secondary outcomes included delayed graft function (DGF), acute‐rejections (AR) within a year, and serum creatinine (Cr) at 1‐year. The propensity‐matched cohort included KTRs on bela ( N = 2612) and tac ( N = 12760). There was no significant difference in the hazard ratio of death (1.03 [0.92, 1.14]), GF (1.07 [0.97, 1.17]), or DCGF (1.11 [0.98, 1.25]). A sensitivity analysis comparing a propensity‐matched cohort of bela + tac ( n = 2033) versus tac ( n = 9004); demonstrated significantly reduced risks of death (0.87 [0.76–1.00], p = 0.043) and GF (0.73 [0.64–0.83] p < 0.001) compared to those on Tac alone. In conclusion, bela + tac seems to be a nephron‐sparing and rejection‐lowering IS regimen with overall improved graft and patient outcomes when compared to the current standard of tacrolimus. Larger Randomized Controlled studies are needed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Transplant Surgery, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Transplant Nephrology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
- Department of Transplant Nephrology, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
ORCID profiles: Stalin Canizares, Adriana Montalvan, Devin Eckhoff, Kalathil K Sureshkumar, Bhavna Chopra
Cite
APA
Canizares, S., Montalvan, A., Eckhoff, D., Sureshkumar, K. K., & Chopra, B. (2025). Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.70075
Vancouver
Canizares S, Montalvan A, Eckhoff D, Sureshkumar KK, Chopra B. Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis. Clinical Transplantation. 2025. doi:10.1111/ctr.70075
BibTeX
@article{Canizares2025,
author = {Canizares, Stalin and Montalvan, Adriana and Eckhoff, Devin and Sureshkumar, Kalathil K and Chopra, Bhavna},
title = {Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70075}
}
EUVIMED